Using this high-throughput screening (HTS) assay, we screened the entry inhibitors from 3500 compounds and identified IMB-1C as a candidate by preventing the binding of S-RBD to ACE2 and blocking pseudotyped SARS-CoV-2 entry and infection. This evidence concerns the gene ACE2 and infection.